[271 Pages Report] By the end of 2022, the global immunochromatography kits market is anticipated to be worth US$ 8.1 Billion, and it will grow at a CAGR of 4.1% to reach an expected valuation of around US$ 12.1 Billion by the year 2032. Kits dominate the worldwide market in 2021, as a product, with a share of around 72.7%, according to a recent analysis by Future Market Insights.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 8.1 Billion |
| Market Value 2032 | US$ 12.1 Billion |
| CAGR 2022-2032 | 4.1% |
| Market Share of Top 5 Countries | 60.7% |
| Key Market Players | Abbott Laboratories, PerkinElmer Inc., Danaher Corporation, Bio-rad Laboratories, F. Hoffmann-La Roche AG, bioMérieux SA, Becton, Dickinson and Company, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and QIAGEN |
The lateral flow test or immunochromatography assay is a simple method for determining if the target analyte is present or missing. The immunochromatography test is the most often utilized test in diagnostic laboratories around the world for rapid patient diagnosis and treatment. The goal of immunochromatography kits is to identify whether a target analyte (such as an antigen or an antibody) is present or missing in a sample in a timely and cost-effective manner.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for immunochromatography kits was approximately 22.9% of the overall ~US$ 33.7 Bn of the global immunoassay market in 2021.
The sale of immunochromatography kits expanded at a CAGR of 4.2% from 2012 to 2021.
Immunochromatography kits are unquestionably one of the most effective analytical tools for on-site target identification. Immunochromatography, which is analogous to a lab-in-a-hand, along with other point-of-need diagnostics, has marked a paradigm change from lab-to-lab to lab-to-sample intended to enable faster decision-making and turnaround time. Immunochromatography kits have a number of characteristics that make them a desirable resource for clinical diagnostics, where they can enhance patient care by facilitating faster treatment and diagnosis decisions.
Widespread acceptance of immunochromatography kits is a result of their efficiency, simplicity, relative affordability, and ability to be used by unskilled individuals. Public health continues to be seriously endangered by hepatitis B. According to the World Health Organization's bulletin from 2018, it is estimated that more than 257 million individuals worldwide have chronic hepatitis B infection and that about 9 million have died from liver failure, hepatocellular carcinoma, liver cirrhosis, and other diseases linked to HBV.
The most widely used serological marker for the screening, diagnosis and evaluation of antiviral therapy for hepatitis B is hepatitis B surface antigen (HBsAg), which is the envelope protein of HBV. Due to their numerous benefits, such as ease of use, low cost, and quick turnaround time, immunochromatography kits have been extensively used in HBV screenings, including self-examinations, medical checks, donating blood, and emergency, and epidemiologic surveys.
The prevalence of cancer is gradually rising, which is anticipated to increase the need for efficient diagnostic tools like immunoassay. This method is important for determining oncogenesis and diagnosing cancer in all of its forms, including benign and malignant cancer. Globally, the use of immunoassay-based diagnostics is steadily rising. The control of the epidemic disease is greatly aided by public awareness initiatives that educate the public about the signs of infectious diseases and how to prevent them. As a result, there is a significant demand for immunochromatography kits due to greater patient awareness.
Because of the aforementioned factors, it is anticipated that from 2022 to 2032, the global immunochromatography kits market will expand at a CAGR of 4.1%.
Since there are more infectious pathogens causing dangerous diseases globally, the development and implementation of rapid diagnostic technologies are urgently needed. Early interventions can make a significant difference in the severity of any disease epidemic by reducing the number of cases.
In recent years, researchers have thought about using more difficult and expensive immunoassay techniques, such as radioimmunoassay and ELISA, in place of the construction of quick, precise, and sensitive approaches.
The majority of these approaches rely on agglutination, immunochromatography (ICG), and several molecular methods. In hospitals, clinics, doctor's offices, and clinical labs, ICG tests are utilized for the qualitative and quantitative detection of a wide range of antigens and antibodies. Additional diagnostic alternatives for parasitic diseases are offered by the novel immunochromatography technology, which may be examined and contrasted with existing conventional diagnostic approaches.
For the diagnosis of parasitic infections such as intestinal parasite protozoa, leishmaniasis, filariasis, trypanosomiasis, trichomoniasis, toxoplasmosis, and others, a number of ICTs have been developed. A number of immunochromatography kits based primarily on the detection of several parasite antigens (and antibodies in certain tests) have recently been developed for the diagnosis of parasitic infections, and the findings are encouraging. Researchers for the identification of various parasite infections have recently evaluated Immunochromatography kits.
Although immunochromatography kits have been around for a while and can be used in the field, there is currently no conclusive data on how well they perform in addressing specific diseases. In terms of performance, scientists concur that immunochromatography kits are a potential tool for diagnosing parasite infections and are reasonably reliable in differentiating between positive and negative people.
Immunochromatography kits are thus a potentially valuable supplement to existing diagnostic tools for parasitic illnesses, providing manufacturers with lucrative opportunities for expansion in the global market during the forecast period.
Principal Consultant
Despite being widely used as the gold standard approach, the use of immunochromatography kits has certain drawbacks.
False-negative results can happen as a result of poor specimen quality, such as when the sample is taken at an inopportune time relative to the onset of the illness, or owing to improper specimen handling or shipping to the laboratory department. False positive results might also be the result of contamination or technical aspects.
Since the detection of an immune response to the virus is an indirect indicator of infection, unlike molecular testing, the development of reliable serological tests and their proper application are crucial to support ongoing public health efforts for effective epidemic prevention.
In order to achieve a quantitative improvement using immunochromatography, additional detecting equipment is needed. The immunoassay method also has a lot of disadvantages when used as an easy and affordable sensing method for domestic or personal use.
Additionally, because it is a one-step assay, the total volume in the test is limited, putting a cap on the sensitivity. Moreover, the analysis is reliant on the characteristics of the sample, including sample viscosity. These are some of the factors restraining the market for immunochromatography kits' adoption globally.
With a market share of 82.8% in all of North America in 2021, the USA presently dominates the region and is expected to sustain this growth throughout the forecast period. This can be attributable to two factors: the simple accessibility of technologically enhanced diagnostic tools, as well as the increased demand for diagnostics brought on by the rise in cancer incidence. The high prevalence of infectious diseases including HIV, TB, and influenza in the region is also driving up the demand for treatment and diagnostic services.
China represents roughly 60.1% of the East Asia market in 2021, with growth at a lucrative CAGR of 4.8% throughout the forecast period. The growing aging population within the country, as well as the wide prevalence of chronic and infectious diseases, presents this growth. Moreover, with the rapidly enhancing healthcare structure in the country, the market for immunochromatography kits is set to advance at a high rate over the forecasted years. Moreover, with the advent of the COVID-19 pandemic, the country presented a greater adoption of immunochromatography kits for the rapid detection of the SARS COV-2 antigen, for the effective management of infection and its prevention.
During the forecast years, Germany is projected to grow at a CAGR of nearly 3.7% in the global immunochromatography kits market. Germany holds the presence of established key players within the global immunochromatography space. Key players like Qiagen have posed a dominant hand in the distribution and development of novel point-of-need diagnosis, thus presenting Germany with a larger market share of around 24.9% within the European market, in 2021. Moreover, growing awareness of infection prevention, as well as the presence of reimbursement for treatment, has aided Germany with lucrative growth opportunities during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Kits are expected to present high growth at a CAGR of 4.2% throughout the forecast period. The benefits of immunochromatography kits include a small sample amount, portable devices, and the absence of the requirement for huge and expensive equipment. Immunochromatography kit technology and design today substantially dismiss previous concerns about their specificity, accuracy, and reproducibility.
The application of immunochromatography kits for the detection of infectious diseases holds a share of around 34.5% in 2021, and this segment is expected to display gradual growth over the forecast period. Immunochromatography assays (ICA), which detect antibodies against pathogens, have been routinely utilized to diagnose a variety of infectious diseases. Rapid direct tests (viral protein screening) have an advantage over indirect ELISA tests (serology) in the case of immunocompromised patients since these patients do not have antibody levels that are high enough to be identified, thus propelling demand for immunochromatography kits for infectious disease detection.
Hospital pharmacies held the highest market share value of 36.5% during the year 2021. Being the prime source for the distribution of immunochromatography kits, this segment is expected to expand at a CAGR of 4.0% during the forecast period. Moreover, point-of-care tests are highly useful for repeat follow-up tests to check treatment progress or for continuous monitoring of a specific analyte. Point-of-care testing substantially shortens the turnaround time, which is crucial and very helpful in addressing serious conditions like heart disease.
To increase their market position, major competitors in the immunochromatography kits market are using a variety of organic and inorganic methods, including alliances, mergers, and acquisitions, geographic growth, and strategic collaborations.
Similarly, recent developments related to companies manufacturing immunochromatography kits have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2012 to 2021 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Application, Usage, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global immunochromatography kits market is estimated to be worth US$ 8.1 Billion in 2022 and is set to expand 1.5X over the next ten years.
The immunochromatography kits market is expected to reach US$ 12.1 Billion by end of 2032 at a CAGR of 4.1%.
Growing geriatric population, rising burden of chronic and infectious diseases, and growing awareness regarding point-of-need diagnostics, are some of the key trends in this market.
By region, North America holds the highest market share generating revenue of close to US$ 3.2 Billion in 2021, in the global immunochromatography kits market.
Europe accounts for about 24.1% of the global immunochromatography kits market in 2021 and is projected to grow with a CAGR of 4.0% during the forecast period.
The US, China, Japan, India, and Germany are the top five countries, which are expected to drive demand in the immunochromatography kits market.
Abbott Laboratories, PerkinElmer Inc., Danaher Corporation, Bio-rad Laboratories, F. Hoffmann-La Roche AG, bioMérieux SA, Becton, Dickinson and Company, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and QIAGEN, are some of the key players in the immunochromatography kits industry.
From 2012 to 2021, the market for immunochromatography kits expanded at the rate of 4.2% CAGR.
The immunochromatography kits market in South Asia is expected to grow at 4.7% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 4.9% during the forecasted years.
1. Executive Summary | Immunochromatography Kits Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption Analysis
4.2. Regulatory Landscape
4.3. Adoption of Point-of-Care Testing
4.4. PESTEL Analysis
4.5. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Immunoassay Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increasing Prevalence of Chronic and Infectious Diseases
5.2.2. Growing Elderly Population
5.2.3. Rising Adoption of Immunochromatography Kits
5.2.4. Technological Advancements
5.2.5. Presence of Alternative Test Kits as Substitute Products
5.2.6. Product Accessibility and Cost
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Application
6.1.3. By Distribution Channel
6.1.4. By Country
6.2. 2021 Market Scenario
7. Global Market Volume (Units) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Volume (Units) Analysis, 2012 to 2021
7.2. Current and Future Market Volume (Units) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis By Product
8.2. Pricing Break-up
8.2.1. Manufacturer-Level Pricing
8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
8.4. Pricing Assumptions
9. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
9.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021
9.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2022 to 2032
10.3.1. Readers
10.3.2. Kits
10.4. Market Attractiveness Analysis By Product
11. Global Market Analysis By Application
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Application, 2012 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2022 to 2032
11.3.1. Sexually Transmitted Diseases
11.3.2. Infectious Diseases
11.3.3. Diabetes
11.3.4. Pregnancy Testing
11.3.5. Drug Abuse Testing
11.3.6. Others
11.4. Market Attractiveness Analysis By Application
12. Global Market Analysis By Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2012 to 2021
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Supermarket/Hypermarket
12.3.4. E-Commerce
12.4. Market Attractiveness Analysis By Distribution Channel
13. Global Market Analysis By Region
13.1. Introduction
13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2012 to 2021
13.3. Current and Future Market Value (US$ Million) and Volume (Units) Projections, 2022 to 2032
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021
14.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032
14.3.1. By Country
14.3.1.1. The USA
14.3.1.2. Canada
14.3.2. By Product
14.3.3. By Application
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Application
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country-Level Analysis & Forecast
14.7.1. The USA Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Product
14.7.1.2.2. By Application
14.7.1.2.3. By Distribution Channel
14.7.2. Canada Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Product
14.7.2.2.2. By Application
14.7.2.2.3. By Distribution Channel
15. Latin America Market Analysis
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021
15.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032
15.3.1. By Country
15.3.1.1. Mexico
15.3.1.2. Brazil
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Product
15.3.3. By Application
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Application
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country-Level Analysis & Forecast
15.7.1. Mexico Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Product
15.7.1.2.2. By Application
15.7.1.2.3. By Distribution Channel
15.7.2. Brazil Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Product
15.7.2.2.2. By Application
15.7.2.2.3. By Distribution Channel
15.7.3. Argentina Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Product
15.7.3.2.2. By Application
15.7.3.2.3. By Distribution Channel
16. Europe Market Analysis
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021
16.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. The UK
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. By Product
16.3.3. By Application
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Application
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country-Level Analysis & Forecast
16.7.1. Germany Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Product
16.7.1.2.2. By Application
16.7.1.2.3. By Distribution Channel
16.7.2. Italy Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Product
16.7.2.2.2. By Application
16.7.2.2.3. By Distribution Channel
16.7.3. France Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Product
16.7.3.2.2. By Application
16.7.3.2.3. By Distribution Channel
16.7.4. The UK Market Analysis
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Product
16.7.4.2.2. By Application
16.7.4.2.3. By Distribution Channel
16.7.5. Spain Market Analysis
16.7.5.1. Introduction
16.7.5.2. Market Analysis and Forecast by Market Taxonomy
16.7.5.2.1. By Product
16.7.5.2.2. By Application
16.7.5.2.3. By Distribution Channel
16.7.6. BENELUX Market Analysis
16.7.6.1. Introduction
16.7.6.2. Market Analysis and Forecast by Market Taxonomy
16.7.6.2.1. By Product
16.7.6.2.2. By Application
16.7.6.2.3. By Distribution Channel
16.7.7. Russia Market Analysis
16.7.7.1. Introduction
16.7.7.2. Market Analysis and Forecast by Market Taxonomy
16.7.7.2.1. By Product
16.7.7.2.2. By Application
16.7.7.2.3. By Distribution Channel
17. East Asia Market Analysis
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021
17.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Product
17.3.3. By Application
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Application
17.4.4. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. China Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Product
17.7.1.2.2. By Application
17.7.1.2.3. By Distribution Channel
17.7.2. Japan Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Product
17.7.2.2.2. By Application
17.7.2.2.3. By Distribution Channel
17.7.3. South Korea Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Product
17.7.3.2.2. By Application
17.7.3.2.3. By Distribution Channel
18. South Asia Market Analysis
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021
18.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Malaysia
18.3.1.4. Thailand
18.3.1.5. Rest of South Asia
18.3.2. By Product
18.3.3. By Application
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Application
18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Country-Level Analysis & Forecast
18.7.1. India Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Product
18.7.1.2.2. By Application
18.7.1.2.3. By Distribution Channel
18.7.2. Indonesia Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Product
18.7.2.2.2. By Application
18.7.2.2.3. By Distribution Channel
18.7.3. Malaysia Market Analysis
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Product
18.7.3.2.2. By Application
18.7.3.2.3. By Distribution Channel
18.7.4. Thailand Market Analysis
18.7.4.1. Introduction
18.7.4.2. Market Analysis and Forecast by Market Taxonomy
18.7.4.2.1. By Product
18.7.4.2.2. By Application
18.7.4.2.3. By Distribution Channel
19. Oceania Market Analysis
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021
19.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Product
19.3.3. By Application
19.3.4. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Application
19.4.4. By Distribution Channel
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
19.7. Country-Level Analysis & Forecast
19.7.1. Australia Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Product
19.7.1.2.2. By Application
19.7.1.2.3. By Distribution Channel
19.7.2. New Zealand Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Product
19.7.2.2.2. By Application
19.7.2.2.3. By Distribution Channel
20. Middle East and Africa (MEA) Market Analysis
20.1. Introduction
20.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021
20.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Turkey
20.3.1.3. North Africa
20.3.1.4. South Africa
20.3.1.5. Rest of Middle East and Africa
20.3.2. By Product
20.3.3. By Application
20.3.4. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Application
20.4.4. By Distribution Channel
20.5. Market Trends
20.6. Drivers and Restraints - Impact Analysis
20.7. Country-Level Analysis & Forecast
20.7.1. GCC Countries Market Analysis
20.7.1.1. Introduction
20.7.1.2. Market Analysis and Forecast by Market Taxonomy
20.7.1.2.1. By Product
20.7.1.2.2. By Application
20.7.1.2.3. By Distribution Channel
20.7.2. Turkey Market Analysis
20.7.2.1. Introduction
20.7.2.2. Market Analysis and Forecast by Market Taxonomy
20.7.2.2.1. By Product
20.7.2.2.2. By Application
20.7.2.2.3. By Distribution Channel
20.7.3. South Africa Market Analysis
20.7.3.1. Introduction
20.7.3.2. Market Analysis and Forecast by Market Taxonomy
20.7.3.2.1. By Product
20.7.3.2.2. By Application
20.7.3.2.3. By Distribution Channel
20.7.4. North Africa Market Analysis
20.7.4.1. Introduction
20.7.4.2. Market Analysis and Forecast by Market Taxonomy
20.7.4.2.1. By Product
20.7.4.2.2. By Application
20.7.4.2.3. By Distribution Channel
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive
22.3.1. Abbott Laboratories
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Sales Footprint
22.3.1.4. Key Financials
22.3.1.5. SWOT Analysis
22.3.1.6. Strategy Overview
22.3.2. PerkinElmer Inc.
22.3.2.1. Overview
22.3.2.2. Product Portfolio
22.3.2.3. Sales Footprint
22.3.2.4. Key Financials
22.3.2.5. SWOT Analysis
22.3.2.6. Strategy Overview
22.3.3. Danaher Corporation
22.3.3.1. Overview
22.3.3.2. Product Portfolio
22.3.3.3. Sales Footprint
22.3.3.4. Key Financials
22.3.3.5. SWOT Analysis
22.3.3.6. Strategy Overview
22.3.4. Bio-Rad Laboratories
22.3.4.1. Overview
22.3.4.2. Product Portfolio
22.3.4.3. Sales Footprint
22.3.4.4. Key Financials
22.3.4.5. SWOT Analysis
22.3.4.6. Strategy Overview
22.3.5. F. Hoffmann-La Roche AG
22.3.5.1. Overview
22.3.5.2. Product Portfolio
22.3.5.3. Sales Footprint
22.3.5.4. Key Financials
22.3.5.5. SWOT Analysis
22.3.5.6. Strategy Overview
22.3.6. BioMérieux SA
22.3.6.1. Overview
22.3.6.2. Product Portfolio
22.3.6.3. Sales Footprint
22.3.6.4. Key Financials
22.3.6.5. SWOT Analysis
22.3.6.6. Strategy Overview
22.3.7. Becton, Dickinson, and Company
22.3.7.1. Overview
22.3.7.2. Product Portfolio
22.3.7.3. Sales Footprint
22.3.7.4. Key Financials
22.3.7.5. SWOT Analysis
22.3.7.6. Strategy Overview
22.3.8. Siemens Healthineers AG
22.3.8.1. Overview
22.3.8.2. Product Portfolio
22.3.8.3. Sales Footprint
22.3.8.4. Key Financials
22.3.8.5. SWOT Analysis
22.3.8.6. Strategy Overview
22.3.9. Thermo Fisher Scientific Inc.
22.3.9.1. Overview
22.3.9.2. Product Portfolio
22.3.9.3. Sales Footprint
22.3.9.4. Key Financials
22.3.9.5. SWOT Analysis
22.3.9.6. Strategy Overview
22.3.10. QIAGEN
22.3.10.1. Overview
22.3.10.2. Product Portfolio
22.3.10.3. Sales Footprint
22.3.10.4. Key Financials
22.3.10.5. SWOT Analysis
22.3.10.6. Strategy Overview
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports
Immunochromatography Kits Market
